Blueprint Medicines requested priority review for this application, which, if granted, could result in a six-month review process... Dec 18
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations... Dec 03
Gavreto is used in treatment of adults with metastatic RET fusion-positive non-small cell lung cancer... Sep 08
GAVRETO, the only once-daily RET-targeted therapy, demonstrated durable efficacy, with complete responses in a subset of patients ... Sep 05
-Advertisements-